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Abstract
Background: Testosterone deficiency is a common occurrence in men with chronic heart failure
(CHF) and may underpin features of advanced disease, including reduced skeletal muscle mass and
fatigue. It is positively correlated with cardiac output and exercise capacity in patients with CHF,
whereas a significant improvement in both these parameters has been observed following
testosterone replacement therapy. Testosterone therapy has also been shown to reduce
circulating levels of inflammatory markers, (TNF-α, sICAM-1 and sVCAM-1) in patients with
established coronary artery disease and testosterone deficiency. This pilot study will assess the
feasibility of a combined exercise rehabilitation and adjunctive testosterone therapy intervention
for evoking improvements in exercise capacity, circulating inflammatory markers, cardiac and
skeletal muscle function, indices of psychological health status and quality of life in hypogonadal
males with chronic heart failure.
Methods/design: Following ethical approval, 36 patients will be randomly allocated to one of two
groups: testosterone or placebo therapy during exercise rehabilitation. A combined programme of
moderate intensity aerobic exercise and resistance (strength) training will be used. The primary
outcome measure is exercise capacity, assessed using an incremental shuttle walk test. Secondary
outcome measures include measures of peak oxygen uptake, cardiac function, lower-limb skeletal
muscle contractile function and oxygenation during exercise, circulating inflammatory markers,
psychological health status and quality of life.
Discussion: Exercise rehabilitation can safely increase exercise capacity in stable CHF patients but
there is a need for studies which are aimed at evaluating the long-term effects of physical training
on functional status, morbidity and mortality. This pilot study will provide valuable preliminary data
on the efficacy of testosterone therapy as an adjunct to exercise rehabilitation on a range of
functional, physiological and health-related outcomes in this patient population. Preliminary data
will be used in the design of a large-scale randomised controlled trial, aimed at informing clinical
practice with respect to optimisation of exercise rehabilitation in this patient group.
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Background
Chronic heart failure (CHF) is a common, debilitating
condition and is a major public health burden in the
Western world. It is a multi-organ disease, involving the
musculoskeletal, respiratory and endocrine systems [1].
CHF most frequently results from coronary artery disease
or hypertension and patients generally experience a con-
tinuing decline in their health, resulting in an increased
frequency of hospitalization and premature death. As car-
diac transplantation is the only option for long-term sur-
vival in patients with CHF, there is a clear requirement for
new strategies aimed at altering disease progression,
relieving symptoms and prolonging life.
Previous studies have reported testosterone deficiency in
men with CHF [2,3], which might underpin features of
advanced CHF such as reduced skeletal muscle mass and
fatigue [3]. Furthermore, testosterone deficiency is posi-
tively correlated with cardiac output [4] and exercise
capacity [3] in patients with CHF and a significant
improvement in both these parameters has been observed
following testosterone replacement therapy [1,3,5].
Although the mechanisms are poorly understood, the
improvement in exercise capacity was shown to be posi-
tively correlated with the increase in serum testosterone
level [3] and was accompanied by a small increase in
internal left ventricular length in a recent study [3]. Addi-
tional evidence from animal studies suggests that anabolic
androgens can attenuate skeletal muscle fatigue in
response to exercise [6]. Testosterone replacement therapy
has also been shown to reduce circulating levels of inflam-
matory mediators, such as TNF-α and IL-1β as well as total
cholesterol in patients with established coronary artery
disease (CAD) and testosterone deficiency [7,8]. Circulat-
ing levels of inflammatory mediators are elevated in CHF
and may be related to endothelial dysfunction and clini-
cal deterioration in these patients.
Interestingly, chronic administration of low physiologic
replacement doses of testosterone can delay the time to
ischaemic threshold during treadmill walking in elderly
males with established CAD [7]. A rapid mode of action is
indicated, as improvements in ischaemic threshold have
been observed after as little as one month of intramuscu-
lar testosterone replacement compared with placebo [7].
As testosterone is a vasodilator, this could explain its anti-
ischemic effects on cardiac function during exercise. How-
ever, it is currently unknown whether the vasodilatory
effects of testosterone can influence the fatigability of skel-
etal muscle in a similar fashion.
It is now widely accepted that exercise training can safely
increase exercise capacity in stable CHF patients [9]. An
improvement in skeletal muscle strength and endurance
has been reported after resistance training regimens
[10,11]. More recent studies have also reported improve-
ments in dynamic quadriceps and hamstrings strength
and endurance following combined aerobic and resist-
ance training programmes [12] and provided evidence
that this combined training approach is superior to aero-
bic training alone for improvement of left ventricular
function in patients with CHF [13]. There is also evidence
that short-term programmes of exercise training lasting
for 12 weeks can reduce the circulating levels of inflam-
matory mediators such as TNF-α, sICAM-1 and sVCAM-1,
which are elevated in CHF [14,15]. However, a need for
more clinical trials aimed at evaluating the long-term
effects of physical training on functional status, morbidity
and mortality in stable CHF patients has recently been
highlighted [9]. Considering the low functional capacity
of male CHF patients [3], an investigation of strategies
that have the potential to augment the response to exer-
cise rehabilitation is warranted in this patient group.
A significant proportion of men with CHF have low testo-
sterone levels. Given the positive effects of testosterone
therapy on exercise capacity in CHF[3] and established
CAD [7], and considering its positive effects on circulating
inflammatory mediators in CAD and testosterone defi-
ciency [7,8], we hypothesize that adjunctive testosterone
therapy will augment the positive effects of exercise reha-
bilitation on these clinical outcomes in hypogonadal
males with stable CHF.
Methods/design
Primary aims of the study
1. To assess the feasibility of a combined exercise rehabil-
itation and adjunctive testosterone therapy intervention
for evoking improvements in exercise capacity, circulating
inflammatory markers, cardiac and skeletal muscle func-
tion, indices of psychological health status and quality of
life in hypogonadal males with chronic heart failure.
2. To obtain estimates of the variability of the primary
outcome measure and an insight into the treatment effect
resulting from combined testosterone therapy/exercise
rehabilitation intervention versus exercise therapy alone,
with the data being used in a subsequent power calcula-
tion for a larger-scale randomised controlled trial.
Patient recruitment
A total of 36 ambulant male patients, over 18 years, with
stable CHF (longer than 6 months) and with a blood tes-
tosterone level of less than 12 nmol.l-1 and symptoms of
hypogonadism will be recruited from clinics at the Royal
Hallamshire Hospital, Sheffield. Patients satisfying the
inclusion/exclusion criteria will be sent a letter, with an
attached patient information sheet. Those patients with a
possible interest in study participation will be invited to
an initial consultation session. This session will answerBMC Cardiovascular Disorders 2006, 6:46 http://www.biomedcentral.com/1471-2261/6/46
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any questions which the patient may have, and will famil-
iarise patients with the study protocol and equipment.
Before entering the trial, each patient will have a thorough
medical examination performed by a Consultant Cardiol-
ogist or Research Registrar, during which details of surgi-
cal history, co-morbid conditions, risk factors and current
medication details will be confirmed. Hormone profiles
and drug use will also be recorded at the beginning of the
trial. Blood pressure will be taken (manual sphygmoma-
nometer) and a resting 12-lead ECG will be performed
with the patient in the supine position. Clinical Trial
Authorisation was granted by the Medicines and Health-
care products Regulatory Agency and Ethical approval
obtained from the North Sheffield Research Ethics Com-
mittee. Informed consent will be obtained from all partic-
ipants before they enter the study.
Randomisation
Patients will be randomly allocated to one of the two
groups: (i) testosterone replacement therapy during a 12
week programme of exercise rehabilitation, or (ii) 12
week programme of exercise rehabilitation with 'placebo
therapy'. Blocked randomisation by a third party, using a
pre-determined randomisation schedule, will be used to
ensure equal distribution of patients throughout the
recruitment process.
Details of power calculations and sample size
Data on exercise capacity (shuttle-walk performance) for
stable CHF patients with testosterone deficiency are una-
vailable. However, a recent preliminary study reported a
statistically significant improvement in shuttle-walk per-
formance in 10 CHF patients following 12 weeks of testo-
sterone therapy [16]. The mean (95% confidence interval)
treatment effect was 65 m (12.6 – 117.4 m). In the pro-
posed study, a main objective of the planned analysis is to
obtain estimates of the variability of the primary outcome
measure and an insight into the treatment effect resulting
from combined testosterone therapy/exercise rehabilita-
tion, with the data being used in a subsequent power cal-
culation for a larger-scale randomised controlled trial.
Allowing for a possible 30% drop-out over the course of
the intervention, recruitment of 18 patients for each group
will enable this sample size calculation to be performed.
Patient inclusion criteria
a. Ambulant male patients with symptoms of hypogonad-
ism
b. Blood testosterone level of less than 12 nmol.l-1
c. Clinically stable CHF (longer than 6 months)
d. Evidence of impairment of left ventricular systolic func-
tion (defined by echocardiography as ejection fraction
less than 35%)
e. Reduced exercise tolerance (limited by fatigue or
breathlessness of cardiac origin)
f. Over 18 years of age
Patient exclusion criteria
a. Unstable angina
b. Recent acute myocardial infarction
c. Decompensated heart failure
d. Haemodynamically significant valvular heart disease
e. Uncontrolled hypertension
f. Renal insufficiency (serum creatinine >2.5 mg.dl-1)
g. Urologic disorders
h. Any orthopaedic or neurologic illness limiting the abil-
ity to exercise
i. A prostate specific antigen (PSA) level above the age
adjusted normal range
j. Patients taking certain concurrent medications might
also be excluded
Supervised exercise
Cycle ergometry will constitute the main component of
the aerobic exercise training regimen. Exercise intensity
will be set at 50% of the maximum short-term exercise
performance, determined by a steep ramp test every 4
weeks (3 minutes of unloaded pedalling, then work rate
increments of 12.5 W every 10 seconds at a crank rate of
60 rpm) [12]. An interval training regimen will be used,
incorporating 30 seconds of exercise with one minute
interpolated rest periods for a total exercise time of 15
minutes (i.e. 10 repeats) [9]. Each aerobic exercise session
will be followed by two sets of low to moderate intensity
resistance exercises for five main muscle groups: quadri-
ceps, hamstrings, pectorals, latissimus dorsi, deltoids. The
supervised exercise sessions will last for approximately
45–50 minutes in total and patients will be required to
attend 3 sessions per week. The venue for supervised exer-
cise will be the Exercise Science Laboratory at Sheffield
Hallam University, which has showering facilities and is
on a major bus route close to the City centre.BMC Cardiovascular Disorders 2006, 6:46 http://www.biomedcentral.com/1471-2261/6/46
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Testosterone replacement therapy
Patients will be administered testosterone therapy or pla-
cebo in an identical fashion and will be blinded to which
treatment they are receiving. Testosterone (Sustanon 100,
100 mg testosterone/ml; Organon Laboratories Ltd, Cam-
bridge, UK) or placebo (1 ml of 0.9% normal saline) in an
identical syringe will be given by deep intramuscular
injection to the buttock every two weeks by a member of
the research staff not involved in the delivery of super-
vised exercise or assessment of outcomes. Patients will be
blinded to the identity of the injection and the drug will
be drawn up away from the patient.
Outcome measures
Unless otherwise stated, outcome measures will be
assessed at baseline and 12 weeks in all patients. Members
of the research team responsible for assessment of the pri-
mary and secondary outcomes and for delivering the
supervised exercise training will be blinded to group allo-
cation.
Primary outcome measure
Exercise capacity
The primary outcome measure is exercise capacity,
assessed using the incremental shuttle walk test (ISWT), as
described in our recently published work [3]. Two tests
will be performed prior to starting treatment, one at the
screening visit and the second before randomisation,
which will be used as the baseline result in subsequent
analysis. The ISWT is a symptom-limited exercise test with
a progressive increase in workload designed to allow sub-
jects to achieve maximum effort tolerance. Subjects walk
back and forth along a horizontal 10 metre course,
marked out by two cones and must complete the shuttle
before a pre-recorded signal from a cassette player, which
shortens incrementally after each shuttle. The end-point
(distance walked in metres) is reached when the subject
fails to complete the shuttle before the signal. The ISWT
has been evaluated in patients with chronic heart failure,
as an alternative to cardiopulmonary exercise testing and
the traditional 6-minute walk test. It is highly reproduci-
ble, preferred by patients, correlates strongly with peak
VO2 (r = 0.84, p < 0.0001) and, after 17 months follow up,
was shown to predict event free survival.
Other outcome measures
Cardiopulmonary function, skeletal muscle and cardiac function
Peak oxygen consumption ( O2) will be assessed using
incremental cycle ergometry (Excalibur, Lode, Groningen,
The Netherlands). The test will begin at a power output of
25 W and increase by 25 W every 3 minutes to maximal
exercise tolerance. The test will be terminated when the
patient becomes restricted by clinical symptoms or the
crank rate of 60 rpm cannot be maintained. Blood pres-
sure, heart rate, perceived exertion (Borg scale range 6–20)
and 12-lead ECG recordings (Marquette CaSE 15, Wiscon-
sin, U.S.A.) will be made after 10 minutes of supine rest
and within the last 30 seconds of each work-rate incre-
ment. Pulmonary gas exchange variables will be measured
breath-by-breath (CaSE EX670 PulmoLab, Kent, U.K.) for
assessment of peak  O2 and ventilatory threshold (VT).
VT is used to detect the beginning of excess CO2 produc-
tion resulting from the buffering of H+ arising from lactic
acid production. Local muscle haemoglobin saturation
will be monitored at rest, during exercise and recovery
using near infrared spectroscopy (NIRS; NIRO 300,
Hamamatsu, Welwyn Garden, UK). This is a non-invasive
technique, in which a light emitting/detecting probe is
placed on the skin over the vastus lateralis muscle. The
NIRS signal is mainly derived from the haemoglobin in
the microvasculature (precapillary, capillary, postcapil-
lary) of the sampled tissue and reflects local tissue oxygen-
ation.
Dynamic muscular strength and endurance of the domi-
nant leg quadriceps and hamstrings will be measured
using an isokinetic dynamometer (Biodex System 3
dynamometer, Biodex Medical, NY, USA). The test proto-
col will comprise a 5-minute warm-up on a cycle ergom-
eter, 3 repetitions at an angular velocity of 1.0 rad.s-1, 5
repetitions at 3.0 rad.s-1 and 20 repetitions at 5.3 rad.s-1,
followed by a cool-down on a cycle ergometer. A 2-
minute rest period will be applied between each set of rep-
etitions and the main outcome measures will be peak
torque and total amount of muscular work (endurance)
performed at each angular velocity. This protocol was
recently shown to be safe for measuring skeletal muscle
strength and endurance in CHF patients [12]. This proto-
col will take approximately 15 – 20 minutes to complete.
Isometric strength of the forearm muscles will also be
assessed using a hand-grip dynamometer.
Morphological changes in cardiac function, with special
emphasis on long axis function, will be assessed using 2D
Doppler echocardiographic scanning techniques [17].
Circulating adhesion molecules and inflammatory 
mediators
Venous blood samples, for analysis of total testosterone,
sex hormone binding globulin, soluble adhesion mole-
cules (sICAM-1, sVCAM-1) and the systemic inflamma-
tory mediators (TNF-α and CRP) by commercially-
available enzyme immunoassay kits, will be collected
after an overnight fast between 0800 and 0930. Full blood
count, glucose concentration, brain natiuretic peptide,
and lipid profiles will also be measured at these time
points using hospital assays. All blood samples will be
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Flow chart showing the study design Figure 1
Flow chart showing the study design.
Cases ascertained by clinicians and outpatient nurses
Confirmation of medical eligibility 
Agree to participate 
Familiarisation visit 
-----------------------   Baseline assessment of all outcomes (week 0)   -----------------------
Randomisation into groups
Exercise + testosterone therapy Exercise therapy alone 
-------   Week 4 intervention assessment of testosterone status and PSA levels    ------- 
Exercise + testosterone therapy Exercise therapy alone 
-------    Week 8 intervention assessment of testosterone status and PSA levels  -------- 
Exercise + testosterone therapy Exercise therapy alone 
-------------------  Post-intervention assessment of all outcomes (week 13)  --------------------BMC Cardiovascular Disorders 2006, 6:46 http://www.biomedcentral.com/1471-2261/6/46
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collected at least 72 hours after the last supervised exercise
bout. Bioavailable testosterone will be calculated by a
modification of the method described by Tremblay and
Dube [18]. Additional blood samples will be collected
during weeks 4 and 8 of the intervention, for analysis of
testosterone status and PSA levels.
Psychological health status and quality of life
Both CHF and androgen deficiency are characterised by
low mood and depression, which is improved by testo-
sterone replacement therapy in testosterone deficient sub-
jects. Thus, at baseline and 12 weeks, patients will be
asked to complete the Minnesota living with heart failure
questionnaire, the SF-36 v2  Health Survey, the Beck
Depression Inventory and the Androgen Deficiency in the
Adult Male Screening Questionnaire. Physical activity
behaviour in everyday life will be measured at baseline, 4,
8, and 12 weeks by the Community Healthy Activities
Model Program for Seniors Questionnaire (CHAMPS)
Physical Activity Questionnaire for older adults. After the
intervention, patients will also be interviewed about their
subjective experiences and views on which aspects of the
intervention worked and which aspects could be
improved.
Analysis of results
As previously stated, a main objective of the planned anal-
ysis is to obtain estimates of the variability of the primary
outcome measure and an insight into the treatment effect
resulting from combined testosterone therapy/exercise
rehabilitation, with the data being used in a subsequent
power calculation for a larger-scale randomised control-
led trial. Primary and secondary outcomes will also be
compared at each follow-up point using analysis of covar-
iance procedures, with baseline values being used as the
covariate. In addition, bivariate relationships between
physical activity dose and other outcome variables will be
analysed using appropriate correlation techniques. Statis-
tical significance will be set at p < 0.05. All data will be
analysed using the SPSS statistical package (SPSS UK Ltd,
Woking, U.K.).
Discussion
The rapidly growing ageing population in Western socie-
ties will inevitably be receiving pharmacological therapy
for chronic heart conditions and vascular diseases. How-
ever, such individuals can still benefit greatly from engag-
ing in a physically active lifestyle. This highlights the need
for more studies into the benefits and risks of combined
programmes of exercise rehabilitation and pharmacologi-
cal therapies to build a strong foundation for evidence-
based therapy.
Testosterone deficiency is common in men with CHF and
could influence the adverse effects of the condition on
skeletal muscle size and fatigability. We have recently
completed a proof-of-concept clinical study showing that
testosterone replacement therapy improves effort toler-
ance in men with CHF [3]. However, the full potential of
this therapeutic approach for improving physical function
and quality of life in patients with CHF is not yet known.
This pilot study will provide valuable preliminary data on
the efficacy of testosterone therapy as an adjunct to exer-
cise rehabilitation on a range of functional, physiological
and health-related outcomes, with the preliminary data
being used in the design of a larger-scale trial. The pro-
posed investigation is very timely and we expect the
results to ultimately inform clinical practice with respect
to optimisation of exercise rehabilitation in this patient
group.
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